Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Prestige Consumer Healthcare (PBH) EBITDA: 2009-2025

Historic EBITDA for Prestige Consumer Healthcare (PBH) over the last 17 years, with Sep 2025 value amounting to $42.9 million.

  • Prestige Consumer Healthcare's EBITDA fell 27.56% to $42.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $195.8 million, marking a year-over-year decrease of 9.11%. This contributed to the annual value of $211.4 million for FY2025, which is 2.44% up from last year.
  • As of Q3 2025, Prestige Consumer Healthcare's EBITDA stood at $42.9 million, which was down 18.92% from $52.9 million recorded in Q2 2025.
  • Prestige Consumer Healthcare's 5-year EBITDA high stood at $60.5 million for Q4 2023, and its period low was -$242.6 million during Q1 2023.
  • For the 3-year period, Prestige Consumer Healthcare's EBITDA averaged around $24.6 million, with its median value being $52.2 million (2024).
  • As far as peak fluctuations go, Prestige Consumer Healthcare's EBITDA tumbled by 531.25% in 2023, and later surged by 117.93% in 2024.
  • Prestige Consumer Healthcare's EBITDA (Quarterly) stood at $51.4 million in 2021, then increased by 14.57% to $58.9 million in 2022, then increased by 2.70% to $60.5 million in 2023, then fell by 21.66% to $47.4 million in 2024, then decreased by 27.56% to $42.9 million in 2025.
  • Its EBITDA stands at $42.9 million for Q3 2025, versus $52.9 million for Q2 2025 and $52.6 million for Q1 2025.